Header Logo

Connection

SETH LERNER to Follow-Up Studies

Back to Details
This is a "connection" page, showing publications SETH LERNER has written about Follow-Up Studies.
SETH LERNER
Connection Strength
0.690
Follow-Up Studies
  1. Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol. 2015 Jun; 111(7):923-8.
    View in: PubMed
    Score: 0.064
  2. Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int. 2015 Jul; 116(1):44-9.
    View in: PubMed
    Score: 0.064
  3. A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila). 2011 Oct; 4(10):1580-9.
    View in: PubMed
    Score: 0.050
  4. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer. J Urol. 2007 May; 177(5):1727-31.
    View in: PubMed
    Score: 0.037
  5. Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol. 2006 Dec; 50(6):1254-60; discussion 1261-2.
    View in: PubMed
    Score: 0.035
  6. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Jul; 212(1):74-86.
    View in: PubMed
    Score: 0.030
  7. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004 Mar 15; 22(6):1014-24.
    View in: PubMed
    Score: 0.030
  8. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol. 2001 May; 165(5):1473-9.
    View in: PubMed
    Score: 0.024
  9. Rebuilding the lower urinary tract after cystectomy: a roadmap for patient selection and counseling. Semin Urol Oncol. 2001 Feb; 19(1):24-36.
    View in: PubMed
    Score: 0.024
  10. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology. 2001 Jan; 57(1):60-5.
    View in: PubMed
    Score: 0.024
  11. Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res. 2001 Jan-Feb; 21(1B):575-8.
    View in: PubMed
    Score: 0.024
  12. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology. 2000 Nov 01; 56(5):735-40.
    View in: PubMed
    Score: 0.023
  13. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients. Clin Cancer Res. 1999 Sep; 5(9):2520-5.
    View in: PubMed
    Score: 0.022
  14. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA. 2018 05 08; 319(18):1880-1888.
    View in: PubMed
    Score: 0.020
  15. Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. Cancer. 2017 Mar 01; 123(5):794-801.
    View in: PubMed
    Score: 0.018
  16. Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. Urol Oncol. 2016 Jan; 34(1):4.e11-7.
    View in: PubMed
    Score: 0.016
  17. Educational opportunities in bladder cancer: increasing cystoscopic adherence and the availability of smoking-cessation programs. J Cancer Educ. 2014 Dec; 29(4):739-45.
    View in: PubMed
    Score: 0.016
  18. The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. J Urol. 1993 Apr; 149(4):758-64; discussion 764-5.
    View in: PubMed
    Score: 0.014
  19. Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. BJU Int. 2013 Jun; 111(8):1215-21.
    View in: PubMed
    Score: 0.014
  20. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol. 2012 Dec; 188(6):2391-7.
    View in: PubMed
    Score: 0.013
  21. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011 Sep 01; 29(25):3443-9.
    View in: PubMed
    Score: 0.012
  22. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urol Oncol. 2013 May; 31(4):480-6.
    View in: PubMed
    Score: 0.012
  23. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. J Urol. 2011 Feb; 185(2):456-61.
    View in: PubMed
    Score: 0.012
  24. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. BJU Int. 2011 Sep; 108(5):687-92.
    View in: PubMed
    Score: 0.012
  25. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res. 2010 Sep 01; 16(17):4461-7.
    View in: PubMed
    Score: 0.012
  26. Outcome of combined liver and kidney transplantation in hepatitis C: a single-center long-term follow-up experience. Transplant Proc. 2009 Jun; 41(5):1713-6.
    View in: PubMed
    Score: 0.011
  27. Blood vessel matrix: a new alternative for abdominal wall reconstruction. Hernia. 2008 Aug; 12(4):351-8.
    View in: PubMed
    Score: 0.010
  28. Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival. BJU Int. 2008 Feb; 101(4):450-4.
    View in: PubMed
    Score: 0.009
  29. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol. 2006 Jun; 175(6):2048-53; discussion 2053.
    View in: PubMed
    Score: 0.009
  30. Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. Urology. 2003 Feb; 61(2):359-64.
    View in: PubMed
    Score: 0.007
  31. Significance of the levels of bone marrow lymphoid infiltrate in chronic lymphocytic leukemia patients with nodular partial remission. Leukemia. 2002 Apr; 16(4):632-5.
    View in: PubMed
    Score: 0.006
  32. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer. 2001 Dec 15; 92(12):2985-92.
    View in: PubMed
    Score: 0.006
  33. Predictors of survival after In vivo split liver transplantation: analysis of 110 consecutive patients. Ann Surg. 2000 Sep; 232(3):312-23.
    View in: PubMed
    Score: 0.006
  34. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998 Aug 15; 92(4):1165-71.
    View in: PubMed
    Score: 0.005
  35. Treatment of staghorn calculi with extracorporeal shock-wave lithotripsy and percutaneous nephrolithotomy. Urology. 1991 Aug; 38(2):145-51.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.